Avadel Pharmaceuticals (AVDL) Research & Development (2016 - 2021)
Historic Research & Development for Avadel Pharmaceuticals (AVDL) over the last 13 years, with Q4 2021 value amounting to $2.1 million.
- Avadel Pharmaceuticals' Research & Development fell 6008.32% to $2.1 million in Q4 2021 from the same period last year, while for Dec 2021 it was $17.1 million, marking a year-over-year decrease of 1632.91%. This contributed to the annual value of $17.1 million for FY2021, which is 1632.91% down from last year.
- Per Avadel Pharmaceuticals' latest filing, its Research & Development stood at $2.1 million for Q4 2021, which was down 6008.32% from $4.4 million recorded in Q3 2021.
- In the past 5 years, Avadel Pharmaceuticals' Research & Development registered a high of $11.9 million during Q2 2018, and its lowest value of $2.1 million during Q4 2021.
- Over the past 5 years, Avadel Pharmaceuticals' median Research & Development value was $7.0 million (recorded in 2017), while the average stood at $7.2 million.
- Its Research & Development has fluctuated over the past 5 years, first soared by 7505.89% in 2018, then crashed by 6058.1% in 2020.
- Avadel Pharmaceuticals' Research & Development (Quarter) stood at $11.3 million in 2017, then plummeted by 46.26% to $6.1 million in 2018, then grew by 27.46% to $7.8 million in 2019, then plummeted by 31.86% to $5.3 million in 2020, then tumbled by 60.08% to $2.1 million in 2021.
- Its Research & Development was $2.1 million in Q4 2021, compared to $4.4 million in Q3 2021 and $6.8 million in Q2 2021.